(R,S)-N-((R)-1-(5-(2-(1H-indol-3-yl)ethyl)-4-(2,4-dimethoxybenzyl)-4H-1,2,4-triazol-3-yl)-2-(1H-indol-3-yl)ethyl)piperazine-2-carboxamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (R,S)-N-((R)-1-(5-(2-(1H-indol-3-yl)ethyl)-4-(2,4-dimethoxybenzyl)-4H-1,2,4-triazol-3-yl)-2-(1H-indol-3-yl)ethyl)piperazine-2-carboxamide
• 英文别名: (R)-N-(1-(5-(2-(1H-indol-3-yl)ethyl)-4-(2,4-dimethoxybenzyl)-4H-1,2,4-triazol-3-yl)-2-(1H-indol-3-yl)ethyl)piperazine-2-carboxamide；(R)-N-1-((5-(2-(1H-indol-3-yl)ethyl)-4-(2,4-dimethoxybenzyl)-4H-1,2,4-triazol-3-yl)-2-(1H-indol-3-yl)ethyl)piperazine-2-carboxamide；N-[(1R)-1-{4-[(2,4-dimethoxyphenyl)methyl]-5-[2-(1H-indol-3-yl)ethyl]-4H-1,2,4-triazol-3-yl}-2-(1H-indol-3-yl)ethyl]piperazine-2-carboxamide；N-[(1R)-1-[4-[(2,4-dimethoxyphenyl)methyl]-5-[2-(1H-indol-3-yl)ethyl]-1,2,4-triazol-3-yl]-2-(1H-indol-3-yl)ethyl]piperazine-2-carboxamide
• 化学式: C₃₆H₄₀N₈O₃
• 分子量: 632.765
• InChiKey: BEAVQQJSWGACGL-XGDNGBMYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  47
• 可旋转键数：
  12
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  134
• 氢给体数：
  5
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  (R)-1-(5-(2-(1H-indol-3-yl)ethyl)-4-(2,4-dimethoxybenzyl)-4H-1,2,4-triazol-3-yl)-2-(1H-indol-3-yl)ethanamine 、 2-哌嗪羧酸盐酸盐 在 N-甲基吗啉 、 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 (R,S)-N-((R)-1-(5-(2-(1H-indol-3-yl)ethyl)-4-(2,4-dimethoxybenzyl)-4H-1,2,4-triazol-3-yl)-2-(1H-indol-3-yl)ethyl)piperazine-2-carboxamide
  参考文献：
  名称：

  Toward Potent Ghrelin Receptor Ligands Based on Trisubstituted 1,2,4-Triazole Structure. 2. Synthesis and Pharmacological in Vitro and in Vivo Evaluations

  摘要：

  A series of ghrelin receptor ligands based on the trisubstituted 1,2,4-triazole structure were synthesized and evaluated for their in vitro binding and biological activity. In this study, we explored the significance of the aminoisobutyryl (Aib) moiety, a common feature in numerous growth hormone secretagogues described in the literature: Potent agonist and antagonist ligands of the growth hormone secretagogue receptor type la (GHS-R1a) were obtained, i.e., compounds 41 (JMV2894) and 17 (JMV3031). The best compounds were evaluated for their in vivo activity on food intake, after sc injection in rodents. Among the tested compounds, few of them were able to stimulate food intake and some others, i.e., compounds 4 (JMV2959), 17, and 52 (JMV3021), acted as potent in vivo antagonist of hexarelin-stimulated food intake. These compounds did not stimulate growth hormone secretion in rats and furthermore did not antagonize growth hormone secretion induced by hexarelin, revealing that it is possible to modulate food intake without altering growth hormone secretion.

  DOI：

  10.1021/jm0704550

文献信息

• Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors
  申请人：Perrissoud Daniel

  公开号：US20070037857A1

  公开（公告）日：2007-02-15

  The present invention provides novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors according to formula (I) that are useful in the treatment or prophylaxis of physiological and/or pathophysiological conditions in mammals, preferably humans, that are mediated by GHS receptors. The present invention further provides GHS receptor antagonists and agonists that can be used for modulation of these receptors and are useful for treating above conditions, in particular growth retardation, cachexia, short-, medium- and/or long term regulation of energy balance; short-, medium- and/or long term regulation (stimulation and/or inhibition) of food intake; adipogenesis, adiposity and/or obesity; body weight gain and/or reduction; diabetes, diabetes type I, diabetes type II, tumor cell proliferation; inflammation, inflammatory effects, gastric postoperative ileus, postoperative ileus and/or gastrectomy (ghrelin replacement therapy).

  本发明提供了一种新型的三唑衍生物，作为生长激素分泌素受体的胃泌素类似物配体，其符合以下公式（I），可用于治疗或预防哺乳动物，尤其是人类，通过GHS受体介导的生理和/或病理条件。本发明还提供了可用于调节这些受体并用于治疗上述疾病的GHS受体拮抗剂和激动剂，特别是生长迟缓、虚弱、短期、中期和/或长期能量平衡的调节；短期、中期和/或长期食物摄入的调节（刺激和/或抑制）；脂肪生成、脂肪堆积和/或肥胖；体重增加和/或减少；糖尿病、糖尿病I型、糖尿病II型、肿瘤细胞增殖；炎症、炎症效应、胃术后肠梗阻、术后肠梗阻和/或胃切除（胃泌素替代疗法）。
• TRIAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS
  申请人：Perrissoud Daniel

  公开号：US20090042905A1

  公开（公告）日：2009-02-12

  The present invention provides triazole derivatives according to formula (I) as ligands of G-protein coupled receptors (GPCR), which are useful for the study of and/or the treatment or prophylaxis of physiological and/or pathophysiological conditions in mammals, preferably humans, which are mediated by GPCR.

  本发明提供了公式（I）的三唑衍生物作为G蛋白偶联受体（GPCR）的配体，可用于研究和/或治疗或预防哺乳动物，尤其是人类的GPCR介导的生理和/或病理生理状况。
• NOVEL TRIAZOLE DERIVATIVES AS GHRELIN ANALOGUE LIGANDS OF GROWTH HORMONE SECRETAGOGUE RECEPTORS
  申请人：PERRISSOUD Daniel

  公开号：US20100331343A1

  公开（公告）日：2010-12-30

  The present invention provides novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors according to formula (I) that are useful in the treatment or prophylaxis of physiological and/or pathophysiological conditions in mammals, preferably humans, that are mediated by GHS receptors. The present invention further provides GHS receptor antagonists and agonists that can be used for modulation of these receptors and are useful for treating above conditions, in particular growth retardation, cachexia, short-, medium- and/or long term regulation of energy balance; short-, medium- and/or long term regulation (stimulation and/or inhibition) of food intake; adipogenesis, adiposity and/or obesity; body weight gain and/or reduction; diabetes, diabetes type I, diabetes type II, tumor cell proliferation; inflammation, inflammatory effects, gastric postoperative ileus, postoperative ileus and/or gastrectomy (ghrelin replacement therapy).

  本发明提供了一种新型的三唑衍生物，作为ghrelin类生长激素分泌素受体的配体，其化学式为（I），可用于治疗或预防哺乳动物，尤其是人类的生理和/或病理生理状态，这些状态是通过GHS受体介导的。本发明还提供了GHS受体拮抗剂和激动剂，可用于调节这些受体，并用于治疗上述疾病，特别是生长迟缓，消瘦，短期，中期和/或长期调节能量平衡; 短期，中期和/或长期调节（刺激和/或抑制）食物摄入; 脂肪生成，脂肪含量和/或肥胖症; 体重增加和/或减少; 糖尿病，糖尿病I型，糖尿病II型，肿瘤细胞增殖; 炎症，炎症影响，胃术后肠麻痹，术后肠麻痹和/或胃切除（ghrelin替代疗法）。
• US8710089B2
  申请人：——

  公开号：US8710089B2

  公开（公告）日：2014-04-29
• Toward Potent Ghrelin Receptor Ligands Based on Trisubstituted 1,2,4-Triazole Structure. 2. Synthesis and Pharmacological in Vitro and in Vivo Evaluations
  作者：Aline Moulin、Luc Demange、Gilbert Bergé、Didier Gagne、Joanne Ryan、Delphine Mousseaux、Annie Heitz、Daniel Perrissoud、Vittorio Locatelli、Antonio Torsello、Jean-Claude Galleyrand、Jean-Alain Fehrentz、Jean Martinez

  DOI：10.1021/jm0704550

  日期：2007.11.1

  A series of ghrelin receptor ligands based on the trisubstituted 1,2,4-triazole structure were synthesized and evaluated for their in vitro binding and biological activity. In this study, we explored the significance of the aminoisobutyryl (Aib) moiety, a common feature in numerous growth hormone secretagogues described in the literature: Potent agonist and antagonist ligands of the growth hormone secretagogue receptor type la (GHS-R1a) were obtained, i.e., compounds 41 (JMV2894) and 17 (JMV3031). The best compounds were evaluated for their in vivo activity on food intake, after sc injection in rodents. Among the tested compounds, few of them were able to stimulate food intake and some others, i.e., compounds 4 (JMV2959), 17, and 52 (JMV3021), acted as potent in vivo antagonist of hexarelin-stimulated food intake. These compounds did not stimulate growth hormone secretion in rats and furthermore did not antagonize growth hormone secretion induced by hexarelin, revealing that it is possible to modulate food intake without altering growth hormone secretion.